The Cladribine Decision

In this video, Dr Duncan Curley, a Partner in our Patents team, discusses the recent UK Court of Appeal decision on Merck Serono’s cladribine product, Mavenclad. This case highlights some of the issues involved in obtaining a supplementary protection certificate (SPC) for pharmaceuticals. Dr Curley provides an in-depth analysis of the historical background of SPCs, the specific challenges faced by Merck Serono, and the implications of the court’s ruling. This decision underscores the balance between encouraging pharmaceutical innovation and regulating drug prices.